This conversation allows us to understand you as a person first, then a patient, ensuring your B12 therapy is perfectly aligned with your specific needs and wellness objectives
PMCID: PMC2701135
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
The boost of energy is so nice
People with Diagnosed B12 Deficiency or Anemia The most obvious candidates for B12 injections are individuals who have been diagnosed with a B12 deficiency or pernicious anemia
This guide is our commitment to the other side of that equation